MMP9 and cystic fibrosis: Thus, after ivacaftor therapy, the downregulation of MMP9 in CMCs could represent one of the possible positive effects of these CFTR modulators in decreasing disease progression, and it could therefore represent a potential biomarker of the efficacy of the CF therapy.